Bonus BioGroup Ltd.
BBIXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.24 | 0.11 | 0.09 | -0.06 |
| FCF Yield | -25.60% | -32.21% | -17.19% | -3.41% |
| EV / EBITDA | -3.36 | -2.94 | -4.64 | -14.44 |
| Quality | ||||
| ROIC | -162.32% | -73.62% | -54.21% | -66.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.93 | 0.74 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 20.22% | 22.68% | 22.88% | -185.30% |
| Safety | ||||
| Net Debt / EBITDA | -0.13 | 0.06 | 1.19 | 0.76 |
| Interest Coverage | 0.00 | 0.00 | -41.58 | -113.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -211.67 | -355.82 |